What the FDA labels say about taking them together
Selegiline and tranylcypromine
Selegiline's FDA label of August 7, 2024 names tranylcypromine in its warnings section; tranylcypromine's label does not name selegiline itself but warns about its class (MAO inhibitors). The selegiline label: “Serotonin syndrome and hyperpyrexia have been reported with the combined treatment of an antidepressant and a non-selective MAOI or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and …”
Check it at the source: the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.); the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.).
What does the selegiline label say about tranylcypromine?
Selegiline label, warningsSevere CNS toxicity associated with hyperpyrexia and death have been reported with the combination of tricyclic antidepressants and non-selective MAOIs (Phenelzine, Tranylcypromine).
Zelapar label (Bausch Health US, LLC, June 1, 2021), warnings and precautionsSerotonin syndrome and hyperpyrexia have been reported with the combined treatment of an antidepressant (e.g., selective serotonin reuptake inhibitors-SSRIs, serotonin-norepinephrine reuptake inhibitors-SNRIs, tricyclic antidepressants, tetracyclic antidepressants, triazolopyridine antidepressants) and a non-selective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as selegiline (ELDEPRYL), rasagiline (AZILECT), and olanzapine (Zydis) selegiline (ZELAPAR).
Source: FDA drug label (Zelapar, NDA021479), Bausch Health US, LLC, effective June 1, 2021 (SPL set 380d7717-2a79-42f3-a712-efe5e7696ba0), via openFDA
Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed
What does the tranylcypromine label say about selegiline?
Tranylcypromine's label does not name selegiline itself; it warns about its class (MAO inhibitors):
Tranylcypromine label, drug interactionsOther MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs) Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) Tricyclic antidepressants Amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine Contraindicated a SS for all antidepressants For MAOIs, increased MAO inhibition and risk of adverse reactions, SS, and HR g Amphetamines and methylphenidates and derivatives Contraindicated a HR Sympathomimetic drugs** …
Tranylcypromine label, contraindicationsCONTRAINDICATIONS Concomitant use or use in rapid succession with other MAOIs; selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitors; tricyclic antidepressants; sympathomimetic drugs; and numerous other drugs.
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Selegiline | Tranylcypromine | |
|---|---|---|
| Labeled for | Parkinson's disease, Depression | Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.756 per capsule 5 mg capsule | $0.591 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once